AMEX:DXR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. More Details


Snowflake Analysis

Flawless balance sheet and slightly overvalued.

Share Price & News

How has Daxor's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DXR's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

2.7%

DXR

-3.3%

US Medical Equipment

-3.3%

US Market


1 Year Return

61.4%

DXR

13.7%

US Medical Equipment

10.9%

US Market

Return vs Industry: DXR exceeded the US Medical Equipment industry which returned 14.7% over the past year.

Return vs Market: DXR exceeded the US Market which returned 13.1% over the past year.


Shareholder returns

DXRIndustryMarket
7 Day2.7%-3.3%-3.3%
30 Day-6.2%-2.5%-5.7%
90 Day21.0%12.2%8.2%
1 Year61.4%61.4%14.7%13.7%13.4%10.9%
3 Year206.1%203.9%69.0%64.7%34.9%25.9%
5 Year79.7%76.9%140.9%122.6%84.6%63.8%

Price Volatility Vs. Market

How volatile is Daxor's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Daxor undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: DXR ($15.35) is trading below our estimate of fair value ($35.02)

Significantly Below Fair Value: DXR is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: DXR is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: DXR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DXR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DXR is overvalued based on its PB Ratio (5.4x) compared to the US Medical Equipment industry average (3.9x).


Next Steps

Future Growth

How is Daxor forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

26.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Daxor has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Daxor performed over the past 5 years?

36.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DXR is currently unprofitable.

Growing Profit Margin: DXR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DXR is unprofitable, but has reduced losses over the past 5 years at a rate of 36.8% per year.

Accelerating Growth: Unable to compare DXR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DXR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).


Return on Equity

High ROE: DXR has a negative Return on Equity (-40.16%), as it is currently unprofitable.


Next Steps

Financial Health

How is Daxor's financial position?


Financial Position Analysis

Short Term Liabilities: DXR's short term assets ($3.0M) exceed its short term liabilities ($2.9M).

Long Term Liabilities: DXR's short term assets ($3.0M) exceed its long term liabilities ($904.7K).


Debt to Equity History and Analysis

Debt Level: DXR's debt to equity ratio (33.4%) is considered satisfactory.

Reducing Debt: DXR's debt to equity ratio has reduced from 58.1% to 33.4% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable DXR has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: DXR is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 30.5% per year.


Next Steps

Dividend

What is Daxor current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DXR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DXR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DXR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DXR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: DXR is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DXR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

Michael Feldschuh (51 yo)

4yrs

Tenure

US$100,000

Compensation

Mr. Michael Richard Feldschuh has been the Chief Executive Officer and President of Daxor Corp. since September 21, 2016. Mr. Feldschuh served as Acting Chief Executive Officer and President of Daxor Corp. ...


CEO Compensation Analysis

Compensation vs Market: Michael's total compensation ($USD100.00K) is below average for companies of similar size in the US market ($USD601.34K).

Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Michael Feldschuh
Chairman4yrsUS$100.00k3.96%
$ 2.4m
Jonathan Feldschuh
Chief Scientific Officer & Director3.58yrsUS$127.92k0.10%
$ 60.7k
Robert Michel
CFO, Chief Compliance Officer & Corporate Secretary2yrsno data0.084%
$ 50.5k
Kathryn Kornafel
Vice President of Marketing & Commercial Development2.25yrsno datano data
Guido Manzo
Vice President of Sales1.67yrsno datano data

2.1yrs

Average Tenure

55yo

Average Age

Experienced Management: DXR's management team is considered experienced (2.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michael Feldschuh
Chairman4yrsUS$100.00k3.96%
$ 2.4m
Jonathan Feldschuh
Chief Scientific Officer & Director3.58yrsUS$127.92k0.10%
$ 60.7k
Phillip Frost
Chairman of Medical Advisory Boardno datano datano data
James Lombard
Independent Director31.67yrsUS$1.75k0.064%
$ 38.8k
Fred Gilbert
Member of Medical Advisory Boardno datano datano data
James Brassel
Member of Medical Advisory Boardno datano datano data
Edward Feuer
Independent Director4.67yrsUS$2.13k0%
$ 0
Henry Cremisi
Independent Director0.25yrno data0%
$ 0
Joy Goudie
Director0.25yrno datano data

3.6yrs

Average Tenure

63yo

Average Age

Experienced Board: DXR's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.8%.


Top Shareholders

Company Information

Daxor Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Daxor Corporation
  • Ticker: DXR
  • Exchange: AMEX
  • Founded: 1970
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$60.392m
  • Shares outstanding: 3.89m
  • Website: https://www.daxor.com

Location

  • Daxor Corporation
  • Empire State Building
  • Suite 7120
  • New York
  • New York
  • 10118
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DXRAMEX (NYSE MKT LLC)YesCommon StockUSUSDJan 1975

Biography

Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/25 05:50
End of Day Share Price2020/09/24 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.